Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients

Cancer Research

Volumn 59, Issue 5, 1999, Pages 1041-1048

  Rousselot, Philippe ^a   Labaume, Sylvaine ^a   Marolleau, Jean Pierre ^a   Larghero, Jérôme ^a   Noguera, Maria Héléna ^b   Brouet, Jean Claude ^a   Fermand, Jean Paul ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Laboratoire Central d'Hematologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; MELARSOPROL;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; DNA NICK TRANSLATION; DRUG EFFECT; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MYELOMA; PLASMA CELL; PRIORITY JOURNAL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENIC POISONING; ARSENICALS; CELL DIVISION; CELL LINE; CELL SURVIVAL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; KINETICS; LYMPHOCYTE ACTIVATION; MELARSOPROL; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OXIDES; PLASMA CELLS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0033105268     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89: 3354-3360, 1997.
2. 3 induces NB4 cell apoptosis with down-regulation of Bel-2 expression and modulation of PML-RARα/PML proteins. Blood, 88: 1052-1061, 1996.
3. 3 exerts dose-dependent dual effects on APL cells. Blood, 89: 3345-3353, 1997.
4. Zhu, J., Koken, M. H., Quignon, F., Chelbi-Alix, M. K., Degos, L., Wang, Z. Y., Chen, Z., und de The, H. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA, 94: 3978-3983, 1997.
5. Shao, W., Fanelli, M., Ferrara, F. F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W. W., Waxman, S., Pelicci, P. G., Lo Coco, F., Avvisati, G., Testa, U., Peschle, C., Gambacorti-Passerini, C. Neni, C., and Miller, W. H., Jr. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst., 90: 124-133, 1998.
6. Soignet, S., Tong, W. P., Gabrilove, J., Scheinberg, D. A., Pandolfi, P. P., and Warrell, R. P., Jr. Initial clinical study of a novel organic arsenical melarsoprol, in patients with advanced leukemia. Blood, 88 (Suppl. 1): 219a, 1996.
7. Calleja, E., König, A., Warrell, R. P., Jr., and Gabrilove, J. Arsenic trioxide induces apoptosis in K562 chronic myelogenous leukemia cells. Blood, 90 (Suppl. 1): 202b, 1997.
8. Ishitsuka, K., Suzuki, S., Hanada, S., Utsunomiya, A., Takeuchi, S., Takeshita, T., Shimotakahara, S., Nakahara, K., Ohno, N., Uozumi, K., Makino, T., and Arima, T. Arsenic acid as well as retinoic acids have therapeutic potential to adult T cell leukemia. Blood, 90 (Suppl. 1)/ 324a, 1997.
9. Lehmann, S., Bengtzen, S., Paul, A., and Paul, C. Arsenic trioxide induces apoptosis and cytotoxic effects in blast cells from patients with non-M3 AML. Blood, 90 (Suppl. 1): 325a, 1997.
10. Soignet, S. L., Rivi, R., König, A. Tong, W. P., Gabrilove, J., Scheinberg, D. A., Pandolfi, P. P., and Warrell, R. P., Jr. Melarsoprol, an organic arsenical, in the treatment of refractory leukemia: laboratory and clinical results. Blood, 90 (Suppl. 1): 507a, 1997.
11. König, A., Wrazel, L., Warrell, R. P., Jr., Rivi, R., Pandolfi, P. P., Jakubowski, A., and Gabrilove, J. Comparative activity of Melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood, 90: 562-570, 1997.
12. Hallek, M., Bergsagel, P. L., and Anderson, K. C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91: 3-21, 1998.
13. Zhang, X. G., Gaillard, J. P., Robillard, N., Lu, Z. Y., Gu, Z. J., Jourdan, M., Boiron, J. M., Bataille, R., and Klein, B. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood, 83: 3654-3663, 1994.
14. Alexanian, R., and Dimopoulos, M. Drug therapy: the treatment of multiple myeloma. N. Engl. J. Med., 330: 484-489, 1994.
15. Iwato, K., Kawano, M., Asaoku, H., Tanabe, O., Tanaka, H., and Kuramoto, A. Separation of human myeloma cells from bone marrow aspirates in multiple myeloma and their proliferation and M-protein secretion in vitro. Blood, 72: 562-566, 1988.
16. Grillot-Courvalin, C., Labaume, S., and Brauet, J. C. Differentiation by IL2 of a sub-population of human B cells. Scand. J. Immunol., 23: 679-684, 1986.
17. Daniel, M., Koken, M. H., Romagné, O., Barbey, S., Bazarbachi, A. Stadler, M., Guillemin, M. C., Degos, L., Chomienne, C., and de Thé, H. PML protein expression in hematopoietic and acute promyelocylic leukemia cells. Blood, 82: 1858-1867, 1993.
18. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. A novel assay for apoptusis. Flow cytometric detection of phosphatidylserine expression on early apoptolic cells using fluorescein labeled Annexin V. J. Immunol. Methods. 184: 39-51, 1995.
19. Chauhan, D., Pandey, P., Ogata, A., Teoh, G., Treon, S., Urashima, M., Kharbanda, S., and Andersen, K. C. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene. 15: 837-843, 1997.
20. Burri, C., Baltz, T., Giroud, C., Doua, F., Welker, H. A., and Brun, R. Pharmacokinetic properties of the trypanocidal drug Melarsoprol. Chemotherapy. 39: 225-234, 1993.
21. Knapp, W., Dorken, B., and Richer, E. P. (eds.). Leucocyte Typing VI: White Cell Differentiation Antigens. New York: Oxford University Press, 1997.
22. Hunter, C. A., Jennings, K. W., Adams, J. H., Murray, M., and Kennedy, P. G. Sub-curative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis. Lancet. 339: 956-958, 1992.
23. Gambacorta, M., Flenghi, L., Fagioli, M. Pileri, S., Leoncini, L., Bigerna, B., Pacini, R., Tanci, L. N., Pasqualucci, L., Ascani, S., Mencarelli, A., Liso, A., Pelicci, P. G., and Falini, B. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am. J. Pathol., 149: 2023-2035, 1996.
24. Koken, M. H., Puvion-Dutilleul, F., Guillemin, M. C., Viron, A., Linares-Cruz, G., Stuurman, N., de Jong, L., Szostecki, C., Calvo, F., Chomienne, C., Degos, L., Puvion, E., and de Thé, H. The t(15;17) translocation alters a nuclear body in a retinoic acid reversible fashion. EMBO J., 13: 1073-1083, 1994.
25. Wang, Z. G., Rivi, R., Delva, L., König, A., Soignet, S., Scheinberg, D., Gambacorti-Passerini, C., Gabrilove, J. L., Warrell, R. P., Jr., and Pandolfi, P. P. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML- and PML/RARα-independent manner. Blood. 90 (Suppl. 1): 327a, 1997.
26. Look, A. T. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. J. Natl. Cancer Inst., 90: 86-88, 1998.
27. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., and Berenson, J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol., 162: 248-255, 1995.
28. Chauhan, D., Kharhanda, S., Ogata, A., Urashima, M., Teohh G., Robertson, M., Kufe, D. W., and Anderson, K. C. Interleukin-6 inhibits Fas-induced apoptosis and SAP kinase activation in multiple myeloma cells. Blood. 89: 227-234, 1997.
29. Demartis, A., Bernassola, F., Savino, R., Melino, G., and Ciliberto, G. Interleukin-6 receptor super-antagonists are potent inducers of human multiple myeloma cell death. Cancer Res., 56: 4213-4218, 1996.
30. Levy, Y., Labaume, S., Colombel, M., and Brouet, J. C. Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis. Clin. Exp. Immunol., 104: 167-172, 1996.
31. Taetle, R., Dos Santos, B., Akamatsu, K. I., Koishihara, Y., and Ohsugi, Y. Effects of all-trans retinoic acid and anti-receptor antibodies on growth and programmed cell death of human myeloma cells. Clin. Cancer Res., 2: 253-259, 1996.
32. Muraguchi, A., Hirano, T., Tang, B., Matsuda, T., Horii, Y., Nakajima, K., and Kishimoto, T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med., 167: 332-344, 1988.
33. Xie, Z., Zhao, S., Konopleva, M., Ke, S., McQueen, T., Reed, J. C., and Andreeff, M. Melarsoprol and arsenic trioxide increase cell death on doxorubicin-resistant human leukemia and myeloma cells by regulating expression of Bel-2 apoptosis regulatory family. Blood, 90 (Suppl. 1): 495a, 1997.
34. Yang, E., and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88: 386-401, 1996.
35. Cavigelli, M., Li, W. W., Lin, A., Su, B., Yoshioka, K., and Karin, M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J., 15: 6269-6279, 1996.
36. O'Dwyer, P. J., Hamilton, T. C., Yao, K. S., Tew, K. D., and Ozols, R. F. Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. Hematol. Oncol. Clin. N. Am., 9: 383-396, 1995.
37. Epstein, J., Xiao, H., and Oba, B. K. P-Glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood, 74: 913-917, 1989.
38. Snow, E. T. Metal carcinogenesis: mechanistic implications. Pharmacol. Ther., 53: 31-65, 1992.
39. Labaume, S., Chopin, M., Pla, M., and Brouet, J. C. Differential in vitro and in vivo effects of all-trans retinoic acid on the growth of human myeloma cells. Leukemia Lymphoma, 30: 361-366, 1998.